Current clinical management of T2DM primarily relies on insulin therapy and oral hypoglycemic agents, such as α-glucosidase inhibitors (e.g., acarbose), biguanides (e.g., metformin), sulfonylureas (e.g., gliclazide), and DPP-IV inhibitors (e.g., sitagliptin). Here, DPP4 is linked to type 2 diabetes mellitus.